We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -78.00 | -0.65% | 11,948.00 | 11,946.00 | 11,948.00 | 12,144.00 | 11,910.00 | 12,070.00 | 566,213 | 14:15:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.12 | 185.34B |
From Apr 2019 to Apr 2024
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) Friday announced positive results from a Phase III trial of its breast cancer treatment Lynparza.
Metastatic breast cancer patients treated with the drug "showed a statistically-significant and clinically-meaningful improvement" compared with patients who received chemotherapy, AstraZeneca said.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
February 17, 2017 02:30 ET (07:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
